OBIO CAAP Company: Adapsyn Bioscience Completes Financing to Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with Pfizer Inc.

Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.

We are excited to apply our platform to unlock the unique targeting capacity of these evolved compounds and realize new therapeutics. Recent technological advances in machine learning, artificial intelligence, and large-scale genomic and metabolomic analysis are reenergizing the field of natural product drug development, and Adapsyn is excited to be at the forefront of this work.
— Nathan Magarvey, PhD, Founder, Chief Scientific Officer of Adapsyn